RecombinantCXCL12a(SDF-1α),biotinylated
CatalogNo.Size#1009Anti-CXCR4N-terminusAntibody
50185PB-22ug#1012Anti-CXCR42ndExtracellularLoop
50185PB-1010ugAntibody50185PB-5050ug
50185PB-100100ug
BACKGROUNDBACKGROUNDCXCL12aandCXCL12b,alsoknownasStromalCell-DerivedFactor1αand1β(SDF-1αand
SDF-1β),aresmallcytokinesthatbelongtotheintercrinefamily.BothformsofCXCL12areproducedbyalternatesplicingofthesamegene.CXCL12isstronglychemotacticforT-lymphocytesandmonocytes,anditplaysanimportantroleinangiogenesisbyrecruitingendothelialProgenitorcells(EPCs)fromthebonemarrowthroughaCXCR4dependentmechanism.ItisthisfunctionofCXCL12thatmakesitaveryimportantfactorincarcinogenesisandtheneovascularisationlinkedtotumorprogression.CXCL12alsohasaroleintumormetastasiswherecancercellsthatexpressthereceptorCXCR4areattractedtometastasistargettissuesthatreleasetheligand,CXCL12.Inbreastcancer,however,increasedexpressionofCXCL12isassociatedwithareducedriskofdistantmetastasis.ByblockingCXCR4,amajorcoreceptorforHIV-1entry,CXCL12actsasanendogenousinhibitorofCXCR4-tropicHIV-1strains.CXCL12wasshowntobeexpressedinmanytissuesinmiceincludingbrain,thymus,heart,lung,liver,kidney,spleenandbonemarrow.
Source:RecombinanthumanCXCL12aisproducedinE.coli(accessionno.
P48061-2).
ProteinSequence:KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKKLGSGLNDIFEAQKIEWHE
Modification:Biotinylatedenzymaticallyatthelastlysineinthesequence.
MolecularMass:10.4kDabyMassSpec.
Purity:>97%
Activity:EC50=2.5nmdeterminedbyCalciumFluxwithrecombinanthumanCXCR4cells.
MigrationconfirmedwithU937cellsexpressingCXCR4.
EndotoxinLevel:<0.01EUper1ugofproteinbyLALmethod.
Form:Lyophilized.
CarrierProtein:None.
Reconstitution:Recommendedat100ug/mlinsteriledistilledwater.
StABIlityandStorage:12monthsfromdateofreceipt,-20oCto-70oC,assupplied.
1month,2oCto8oC,understerileconditionsafterreconstitution.
3months,-20oCto-70oC,understerileconditionsafterreconstitution.
Forinvitroinvestigationaluseonly.Notforuseindiagnosticortherapeuticprocedures.
